Trial · NCT02279641
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Observed Plasma Concentration (Cmax) | 22 days | Cmax of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170 |
| Primary | Time of Occurrence of Maximum Observed Concentration (Tmax) | 22 days | Tmax of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination |
| Primary | Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24) | 22 days | AUC 0-24 of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170 |
| Primary | Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last) | 22 days | AUC last of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170 |
| Primary | Apparent Terminal Half-life (t1/2) | 22 days | t1/2 of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination |
| Primary | Amount Excreted in Urine as Unchanged Drug or Metabolite (Ae0-24) | 22 days | Ae0-24 of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170 |
| Primary | Renal Clearance of the Drug From Time Zero up to 24 Hours Postdose (CRL0-24) | 22 days | CLR0-24 of Allopurinol/Oxypurinol and RDEA3170 Alone and In Combination |
| Primary | Pharmacodynamics (PD) Profile of Uric Acid From Serum and Urine | 22 days | |
| Primary | Maximum Observed Plasma Concentration (Cmax) | 22 days | Cmax of RDEA3170 Alone and In Combination with Allopurinol |
| Primary | Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24) | 22 days | AUC 0-24 of RDEA3170 Alone and In Combination with Allopurinol |
| Primary | Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last) | 22 days | AUC last of RDEA3170 Alone and In Combination with Allopurinol |
| Primary | Amount Excreted in Urine as Unchanged Drug or Metabolite (Ae0-24) | 22 days | Ae0-24 of RDEA3170 Alone and In Combination with Allopurinol |
| Secondary | Incidence of Treatment-Emergent Adverse Events | 22 days |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02279641/registered